Trials / Completed
CompletedNCT04203693
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Observational Study to Assess the Effectiveness, Safety Profile and Real-life Prescribing and Utilization Patterns of Tildrakizumab (Ilumetri®) in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice. (SAIL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 331 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tildrakizumab | The study physicians will choose the treatment independently of the enrolment in the study according to routine care. |
Timeline
- Start date
- 2019-10-30
- Primary completion
- 2024-05-02
- Completion
- 2024-05-02
- First posted
- 2019-12-18
- Last updated
- 2026-03-02
- Results posted
- 2026-03-02
Locations
41 sites across 6 countries: Austria, Belgium, France, Germany, Italy, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04203693. Inclusion in this directory is not an endorsement.